1. Home
  2. PSN vs PTGX Comparison

PSN vs PTGX Comparison

Compare PSN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parsons Corporation

PSN

Parsons Corporation

N/A

Current Price

$50.55

Market Cap

5.6B

Sector

Technology

ML Signal

N/A

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

N/A

Current Price

$100.00

Market Cap

5.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSN
PTGX
Founded
1944
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.2B
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
PSN
PTGX
Price
$50.55
$100.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
12
Target Price
$83.50
$106.67
AVG Volume (30 Days)
1.2M
759.4K
Earning Date
04-29-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
3.77
N/A
EPS
2.20
N/A
Revenue
$6,364,245,000.00
N/A
Revenue This Year
$6.08
$867.86
Revenue Next Year
$7.63
N/A
P/E Ratio
$22.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$49.38
$39.60
52 Week High
$89.50
$105.69

Technical Indicators

Market Signals
Indicator
PSN
PTGX
Relative Strength Index (RSI) 28.44 63.91
Support Level N/A $76.63
Resistance Level $66.57 $100.00
Average True Range (ATR) 2.03 4.82
MACD -0.82 0.29
Stochastic Oscillator 6.91 68.07

Price Performance

Historical Comparison
PSN
PTGX

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Share on Social Networks: